» Articles » PMID: 38591915

New Treatment Approaches for Infections: Alternatives to Antibiotics and Fecal Microbiota Transplantation

Overview
Journal Gut Microbes
Date 2024 Apr 9
PMID 38591915
Authors
Affiliations
Soon will be listed here.
Abstract

causes a range of debilitating intestinal symptoms that may be fatal. It is particularly problematic as a hospital-acquired infection, causing significant costs to the health care system. Antibiotics, such as vancomycin and fidaxomicin, are still the drugs of choice for infections, but their effectiveness is limited, and microbial interventions are emerging as a new treatment option. This paper focuses on alternative treatment approaches, which are currently in various stages of development and can be divided into four therapeutic strategies. Direct killing of (i) includes beside established antibiotics, less studied bacteriophages, and their derivatives, such as endolysins and tailocins. Restoration of microbiota composition and function (ii) is achieved with fecal microbiota transplantation, which has recently been approved, with standardized defined microbial mixtures, and with probiotics, which have been administered with moderate success. Prevention of deleterious effects of antibiotics on microbiota is achieved with agents for the neutralization of antibiotics that act in the gut and are nearing regulatory approval. Neutralization of toxins (iii) which are crucial virulence factors is achieved with antibodies/antibody fragments or alternative binding proteins. Of these, the monoclonal antibody bezlotoxumab is already in clinical use. Immunomodulation (iv) can help eliminate or prevent infection by interfering with cytokine signaling. Small-molecule agents without bacteriolytic activity are usually selected by drug repurposing and can act via a variety of mechanisms. The multiple treatment options described in this article provide optimism for the future treatment of infection.

Citing Articles

Microbiome Integrity Enhances the Efficacy and Safety of Anticancer Drug.

Mafe A, Busselberg D Biomedicines. 2025; 13(2).

PMID: 40002835 PMC: 11852609. DOI: 10.3390/biomedicines13020422.


Gastroenterological Surgery and Management of Infection: A Review.

Takano T, Aiba H, Kaku M, Kunishima H J Anus Rectum Colon. 2025; 9(1):25-32.

PMID: 39882219 PMC: 11772788. DOI: 10.23922/jarc.2024-078.


Microbes Saving Lives and Reducing Suffering.

Timmis K, Karahan Z, Ramos J, Koren O, Perez-Cobas A, Steward K Microb Biotechnol. 2025; 18(1):e70068.

PMID: 39844583 PMC: 11754571. DOI: 10.1111/1751-7915.70068.


Microbiota transplantation.

Nezhadi J, Fadaee M, Ahmadi S, Kafil H Heliyon. 2024; 10(20):e39047.

PMID: 39640634 PMC: 11620042. DOI: 10.1016/j.heliyon.2024.e39047.


and Gut Microbiota: From Colonization to Infection and Treatment.

Spigaglia P Pathogens. 2024; 13(8).

PMID: 39204246 PMC: 11357127. DOI: 10.3390/pathogens13080646.


References
1.
Reigadas E, van Prehn J, Falcone M, Fitzpatrick F, Vehreschild M, Kuijper E . How to: prophylactic interventions for prevention of Clostridioides difficile infection. Clin Microbiol Infect. 2021; 27(12):1777-1783. DOI: 10.1016/j.cmi.2021.06.037. View

2.
Fujimoto K, Kimura Y, Shimohigoshi M, Satoh T, Sato S, Tremmel G . Metagenome Data on Intestinal Phage-Bacteria Associations Aids the Development of Phage Therapy against Pathobionts. Cell Host Microbe. 2020; 28(3):380-389.e9. DOI: 10.1016/j.chom.2020.06.005. View

3.
Meader E, Mayer M, Steverding D, Carding S, Narbad A . Evaluation of bacteriophage therapy to control Clostridium difficile and toxin production in an in vitro human colon model system. Anaerobe. 2013; 22:25-30. DOI: 10.1016/j.anaerobe.2013.05.001. View

4.
Cole L, Li L, Jetley U, Zhang J, Pacheco K, Ma F . Deciphering the domain specificity of C. difficile toxin neutralizing antibodies. Vaccine. 2019; 37(29):3892-3901. DOI: 10.1016/j.vaccine.2019.05.040. View

5.
Wang S, Deng W, Li F, Chen Y, Wang P . Blockade of T helper 17 cell function ameliorates recurrent Clostridioides difficile infection in mice. Acta Biochim Biophys Sin (Shanghai). 2021; 53(10):1290-1299. DOI: 10.1093/abbs/gmab107. View